On August 7th, 2020, the Food and Drug Administration (FDA) approved the Guardant 360 CDx for comprehensive biomarker testing for patients with any solid tumor. The FDA based their approval on data from the clinical trials FLAURA and AURA3 as clinical validation that patients receiving liquid biopsy biomarker testing with the Guardant360 CDx had similar periods of time without progression as patients who received traditional biomarker testing.

This approval gives patients newfound access to comprehensive biomarker testing that they may otherwise not have been able to receive.

Click here to read the full press release.